彭博：中国突破动物实验界限，赢得全球生物技术竞赛

Investment Rating - The report indicates a positive outlook for the biotechnology industry in China, particularly in the field of gene editing and transgenic animals, suggesting significant growth potential [7][10][18]. Core Insights - China is positioning itself as a global leader in biotechnology by pushing the boundaries of animal experimentation, which has traditionally been dominated by the US and Europe [5][7][18]. - The market for transgenic animals in biomedical research is expected to reach $15 billion by 2024, reflecting a doubling in size over the past decade [10][12]. - The Chinese government has invested approximately $3 billion in the biotechnology sector in 2023, with projections indicating that sales of cell and gene therapies will grow from $300 million last year to $2 billion by 2033 [7][10]. Summary by Sections Regulatory Environment - Unlike the US and Europe, China has a relatively lenient regulatory framework regarding animal experimentation, which facilitates research and development in gene editing [18][19]. - The lack of comprehensive animal welfare laws in China allows for more extensive use of large animals in research, which is becoming increasingly difficult in Western countries due to ethical concerns [18][19]. Market Dynamics - The global market for transgenic animal models has seen significant growth, with estimates suggesting it will reach $15 billion by 2024, driven by advancements in gene editing technologies [10][12]. - Chinese companies such as SineuGene are at the forefront of developing gene-edited animal models for various diseases, including autism and ALS [5][10][24]. Scientific Advancements - The development of SNUG01, a gene therapy derived from pigs, has been approved for human trials, potentially benefiting 90% of ALS patients [4][5]. - Chinese scientists have successfully created genetically modified monkeys and dogs to study complex human diseases, marking a significant advancement in biomedical research [7][19]. Competitive Landscape - The report highlights that China is rapidly advancing in biotechnology, with significant government support and a growing number of research centers dedicated to gene editing and transgenic animal breeding [7][10][18]. - The ability to clone and genetically modify large animals positions China uniquely in the global biotechnology race, as it seeks to reduce reliance on foreign pharmaceutical companies [7][19].